Outlook Therapeutics Inc. Common Stock (OTLK)

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outl…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

17

Website

outlooktherapeutics.com

Fundamentals

1-day range

$0.712$0.8438

Market cap

$170.73M

P/E (trailing)

—

P/E (forward)

-4.73

EPS (trailing)

$-1.13

Dividend yield

—

Beta

0.80

Avg. volume

25.36M

Dividend pay date

March 18, 2019

Forecasts

4 analyst ratings

Outlook Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• OTLK

  Outlook Therapeutics Inc. Common Stock

  $0.645

  ▲ 0.62%
  Market cap $170.73MP/E —
  $0.161$3.39
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $158.19MP/E —
  $0.532$2.35
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $156.62MP/E —
  $4.54$50.4
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34
• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $153.04MP/E —
  $0.5261$2.55
• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $148.77MP/E —
  $1.38$3.54

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

10.94M

Total value held

$2.22M

Institutional holders

52